Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model

Seminars in Cancer Biology

Volumn 13, Issue 4, 2003, Pages 275-281

  Kovar, Heinrich ^a   Ban, Josef ^a   Pospisilova, Sarka ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Drug resistance; Ewing's sarcoma; Minimal residual disease

Indexed keywords

ADENOVIRUS VECTOR; LENTIVIRUS VECTOR; PROTEIN TAF2N; PROTEIN TLS; RETROVIRUS VECTOR; RNA BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; EWS FLI1 FUSION PROTEIN; EWS-FLI1 FUSION PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FLI 1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER ADJUVANT THERAPY; CANCER MODEL; CANCER RESEARCH; CHONDROSARCOMA; DESMOPLASTIC SMALL ROUND CELL TUMOR; DNA BINDING; EWING SARCOMA; GENE DELIVERY SYSTEM; HUMAN; MELANOMA; MYXOSARCOMA; NEUROECTODERM TUMOR; PHENOTYPE; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; TUMOR CELL; TUMOR DIFFERENTIATION; UNDIFFERENTIATED CARCINOMA; ANIMAL; BIOLOGICAL MODEL; GENE THERAPY; GENETICS; METHODOLOGY;

ANIMALS; GENE THERAPY; HUMANS; MODELS, BIOLOGICAL; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA INTERFERENCE; SARCOMA, EWING'S; TRANSCRIPTION FACTORS;

EID: 0346013210     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(03)00041-5     Document Type: Article

References (70)

1. Tijsterman M., Ketting R.F., Plasterk R.H. The genetics of RNA silencing. Annu. Rev. Genet. 36:2002;489-519.
2. Paddison P.J., Caudy A.A., Bernstein E., Hannon G.J., Conklin D.S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16:2002;948-958.
3. Elbashir S.M., Martinez J., Patkaniowska A., Lendeckel W., Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20:2001;6877-6888.
4. Brummelkamp T., Bernards R., Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2:2002;243.
5. Wilda M., Fuchs U., Wossmann W., Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene. 21:2002;5716-5724.
6. Heidenreich O., Krauter J., Riehle H., Hadwiger P., John M., Heil G.et al. AML1/MTG8 oncogene suppression by small, interfering RNAs supports myeloid differentiation of t(821)-positive leukemic cells. Blood. 101:2003;3157-3163.
7. Hoffmann A., Roeder R.G. Cloning and characterization of human TAF20/15. Multiple interactions suggest a central role in TFIID complex formation. J. Biol. Chem. 271:1996;18194-18202.
8. Bertolotti A., Lutz Y., Heard D.J., Chambon P., Tora L. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J. 15:1996;5022-5031.
9. Bertolotti A., Melot T., Acker J., Vigneron M., Delattre O., Tora L. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol. Cell Biol. 18:1998;1489-1497.
10. Chansky H.A., Hu M., Hickstein D.D., Yang L. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res. 61:2001;3586-3590.
11. Knoop L.L., Baker S.J. The splicing factor U1C represses EWS/ FLI-mediated transactivation. J. Biol. Chem. 275:2000;24865-24871.
12. Yang L., Embree L.J., Tsai S., Hickstein D.D. Oncoprotein TLS interacts with serine-arginine proteins involved in RNA splicing. J. Biol. Chem. 273:1998;27761-27764.
13. Yang L., Chansky H.A., Hickstein D.D. EWS(middle dot)Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J. Biol. Chem. 275:2000;37612-37618.
14. Zhang D., Paley A.J., Childs G. The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription. J. Biol. Chem. 273:1998;18086-18091.
15. Calvio C., Neubauer G., Mann M., Lamond A.I. Identification of hnRNP P2 as TLS/FUS using electrospray mass spectrometry. RNA. 1:1995;724-733.
16. Bailly R.A., Bosselut R., Zucman J., Cormier F., Delattre O., Roussel M.et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol. Cell Biol. 14:1994;3230-3241.
17. Feng L., Lee K.A. A repetitive element containing a critical tyrosine residue is required for transcriptional activation by the EWS/ATF1 oncogene. Oncogene. 20:2001;4161-4168.
18. Ohno T., Rao V.N., Reddy E.S. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res. 53:1993;5859-5863.
19. Thompson A.D., Teitell M.A., Arvand A., Denny C.T. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. Oncogene. 18:1999;5506-5513.
20. Delattre O., Zucman J., Plougastel B., Desmaze C., Melot T., Peter M.et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 359:1992;162-165.
21. Arvand A., Denny C.T. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene. 20:2001;5747-5754.
22. Zucman J., Melot T., Desmaze C., Ghysdael J., Plougastel B., Peter M.et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 12:1993;4481-4487.
23. De Alava E., Kawai A., Healey J.H., Fligman I., Meyers P., Huvos A.G.et al. EWS-FLI1 fusion transcript stucture is an independent determinant of prognosis in Ewings sarcoma. J. Clin. Oncol. 16:1998;1248-1255.
24. Zoubek A., Dockhorn Dworniczak B., Delattre O., Christiansen H., Niggli F., Gatterer Menz I.et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J. Clin. Oncol. 14:1996;1245-1251.
25. Sorensen P.H., Shimada H., Liu X.F., Lim J.F., Thomas G., Triche T.J. Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI1 fusion gene. Cancer Res. 55:1995;1385-1392.
26. Teitell M.A., Thompson A.D., Sorensen P.H., Shimada H., Triche T.J., Denny C.T. EWS/ETS fusion genes induce epithelial and neuroectodermal differentiation in NIH 3T3 fibroblasts. Lab. Invest. 79:1999;1535-1543.
27. Lessnick S.L., Dacwag C.S., Golub T.R. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell. 1:2002;393-401.
28. Ambros I.M., Ambros P.F., Strehl S., Kovar H., Gadner H., Salzer Kuntschik M. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer. 67:1991;1886-1893.
29. Dauphinot L., De Oliveira C., Melot T., Sevenet N., Thomas V., Weissman B.E.et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene. 20:2001;3258-3265.
30. Eliazer S., Spencer J., Ye D., Olson E., Ilaria R.L. Jr. Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma. Mol. Cell Biol. 23:2003;482-492.
31. Fukuma M., Okita H., Hata J., Umezawa A. Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene. 22:2003;1-9.
32. Nishimori H., Sasaki Y., Yoshida K., Irifune H., Zembutsu H., Tanaka T. et al. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene. 21:2002;8302-8309.
33. Norton J.D., Deed R.W., Craggs G., Sablitzky F. Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell Biol. 8:1998;58-65.
34. Martinsen B.J., Bronner-Fraser M. Neural crest specification regulated by the helix-loop-helix repressor Id2. Science. 281:1998;988-991.
35. Deneen B., Denny C.T. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene. 20:2001;6731-6741.
36. Kovar H., Auinger A., Jug G., Aryee D., Zoubek A., Salzer Kuntschik M.et al. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene. 8:1993;2683-2690.
37. Kovar H, Jug G, Aryee DNT, Zoubek A, Ambros P, Gruber B, et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997;15.
38. Hahm K.B., Cho K., Lee C., Im Y.H., Chang J., Choi S.G.et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat. Genet. 23:1999;222-227.
39. Matsumoto Y., Tanaka K., Nakatani F., Matsunobu T., Matsuda S., Iwamoto Y. Down regulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes. Br. J. Cancer. 84:2001;768-775.
40. Zwerner J.P., May W.A. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene. 20:2001;626-633.
41. Toretsky J.A., Kalebic T., Blakesley V., LeRoith D., Helman L.J. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts (in process citation). J. Biol. Chem. 272:1997;30822-30827.
42. Wang M., Xie Y., Girnita L., Nilsson G., Dricu A., Wejde J.et al. Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells. Exp. Cell Res. 246:1999;38-46.
43. Girnita L., Girnita A., Wang M., Meis-Kindblom J.M., Kindblom L.G., Larsson O. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells. Oncogene. 19:2000;4298-4301.
44. Scotlandi K., Benini S., Nanni P., Lollini P.L., Nicoletti G., Landuzzi L.et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 58:1998;4127-4131.
45. Tanaka K., Iwakuma T., Harimaya K., Sato H., Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest. 99:1997;239-247.
46. Toretsky J.A., Connell Y., Neckers L., Bhat N.K. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J. Neurooncol. 31:1997;9-16.
47. Kovar H., Aryee D.N., Jug G., Henockl C., Schemper M., Delattre O.et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ. 7:1996;429-437.
48. Dohjima T, Ohno T, Banno Y, Nozawa Y, Wen-yi Y, Shimizu K. Preferential down-regulation of phospholipase C-beta in Ewing's sarcoma cells transfected with antisense EWS-Fli-1. Br J Cancer 2000;82(1):16-9, 82:16-9.
49. Ouchida M., Ohno T., Fujimura Y., Rao V.N., Reddy E.S. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS fusion transcripts. Oncogene. 11:1995;1049-1054.
50. Lambert G., Bertrand J.R., Fattal E., Subra F., Pinto-Alphandary H., Malvy C.et al. EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279:2000;401-406.
51. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:2002;550-553.
52. Miyagishi M., Taira K. U6 promoter driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat. Biotechnol. 20:2002;497-500.
53. Yu J.Y., DeRuiter S.L., Turner D.L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 99:2002;6047-6052.
54. Kawasaki H., Taira K. Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res. 31:2003;700-707.
55. Kovar H., Jug G., Hattinger C., Spahn L., Aryee D.N., Ambros P.F.et al. The ews protein is dispensable for ewing tumor growth. Cancer Res. 61:2001;5992-5997.
56. Vickers T.A., Koo S., Bennett C.F., Crooke S.T., Dean N.M., Baker B.F. Efficient reduction of target RNA's by siRNA and RNase H dependent antisense agents: a comparative analysis. J. Biol. Chem. 278:2003;7108-7118.
57. Zucman-Rossi J., Legoix P., Victor J.M., Lopez B., Thomas G. Chromosome translocation based on illegitimate recombination in human tumors. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11786-11791.
58. Zeng Y., Cullen B.R. RNA interference in human cells is restricted to the cytoplasm. RNA. 8:2002;855-860.
59. Barton G.M., Medzhitov R. Retroviral delivery of small interfering RNA into primary cells. Proc. Natl. Acad. Sci. U.S.A. 99:2002;14943-14945.
60. Devroe E., Silver P.A. Retrovirus-delivered siRNA. BMC Biotechnol. 2:2002;15.
61. Xia H., Mao Q., Paulson H.L., Davidson B.L. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20:2002;1006-1010.
62. Qin X.F., An D.S., Chen I.S., Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. U.S.A. 100:2003;183-188.
63. Hamada M., Ohtsuka T., Kawaida R., Koizumi M., Morita K., Furukawa H.et al. Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev. 12:2002;301-309.
64. Lewis D.L., Hagstrom J.E., Loomis A.G., Wolff J.A., Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32:2002;107-108.
65. Peter M., Magdelenat H., Michon J., Melot T., Oberlin O., Zucker J.M.et al. Sensitive detection of occult Ewing's cells by the reverse transcriptase-polymerase chain reaction. Br. J. Cancer. 72:1995;96-100.
66. Schleiermacher G., Peter M., Oberlin O., Philip T., Rubie H., Mechinaud F.et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J. Clin. Oncol. 21:2003;85-91.
67. Zoubek A., Ladenstein R., Windhager R., Amann G., Fischmeister G., Kager L.et al. Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int. J. Cancer. 79:1998;56-60.
68. Knezevich S.R., Hendson G., Mathers J.A., Carpenter B., Lopez-Terrada D., Brown K.L.et al. Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma. Hum. Pathol. 29:1998;289-294.
69. Maeda G., Masui F., Yokoyama R., Shimoda T., Matsuno Y., Mukai K.et al. Ganglion cells in Ewing's sarcoma following chemotherapy: a case report. Pathol. Int. 48:1998;475-480.
70. Yi H., Fujimura Y., Ouchida M., Prasad D.D., Rao V.N., Reddy E.S. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene. 14:1997;1259-1268.